Hydrogen and Allergies: What the Research Reports

Posted on July 27, 2026

Abstract scientific illustration of soft blue particles orbiting a translucent central core along silver elliptical paths on a clean white background, representing molecular hydrogen and the immune system

Most allergy research spends its energy trying to block one specific molecule — an antibody, a cytokine, a single receptor. A pair of ENT research teams in China tried something almost embarrassingly different: give allergic rhinitis patients hydrogen gas to breathe, then sequence what was actually living in their noses before and after.

That's not a metaphor. It's a real, registered clinical trial, and it's one of several human studies now converging on the same allergy-adjacent territory — nasal irrigation trials, a small human pilot on atopic dermatitis, mouse-model work on asthma, and a short acute-inhalation study in people already diagnosed with asthma and COPD. None of it says hydrogen cures an allergy. Most of it is honest about being early. All of it is worth reporting on carefully, because the signal keeps showing up in the same handful of places: nasal inflammation, skin barrier response, and the Th2-dominant immune overdrive that defines allergic disease in the first place.

Why Allergies Are a Different Kind of Hydrogen Question

Most of the conditions this series has covered — inflammation, cardiovascular health, gut health — involve a body doing too little of something useful, or quietly accumulating oxidative damage over years. Allergic disease runs the other direction. It's an immune system doing too much of the wrong thing: a Th2-skewed overreaction to something that was never actually dangerous — pollen, dust mite protein, a food particle — treated by the immune system as a genuine threat.

That distinction shapes how researchers have approached hydrogen here. Instead of asking whether hydrogen can protect a tissue from damage, allergy researchers have mostly asked a narrower question: can hydrogen calm down an immune response that's already overcorrecting? The two most-studied entry points are the nose — where allergic rhinitis produces the bulk of the human clinical data — and the lower airway, where asthma research remains almost entirely preclinical. A newer, smaller thread looks at skin. We'll walk through all three.

There's a practical reason this reframing is more than semantic. Antihistamines and nasal steroids, the standard tools, work by intercepting the allergic response after it has already started — blocking a receptor, suppressing local inflammation once it's underway. The hydrogen research is chasing something different: whether easing the oxidative and immune conditions that prime the overreaction in the first place can lower the baseline the whole cascade builds on. That's a harder thing to demonstrate, which is part of why the studies lean on measurable markers — eosinophil counts, IgE, symptom scores — rather than on how dramatic the relief feels in the moment.

The Immune Mechanism: A Selective Antioxidant Meets an Overactive Response

Allergic rhinitis, in the language researchers use, is "an allergic reaction dominated by the Th2 immune response in the nasal mucosa" — a definition drawn directly from the background of a 2024 hydrogen-inhalation trial published in the World Allergy Organization Journal. Th2 cells sit near the top of the cascade. They push B cells to produce IgE antibodies, and they release the signaling cytokines — interleukin-4, interleukin-5, interleukin-13 — that recruit eosinophils, the white blood cells responsible for much of the swelling, itching, and mucus overproduction people actually experience as allergic symptoms. In a settled immune system, Th1 and Th2 activity stay roughly balanced. In allergic disease, the scale tips toward Th2 and stays there.

Researchers have increasingly connected that skewed Th1/Th2 balance to environmental exposures, including the makeup of the bacterial communities living inside the nose itself. The immune system, in other words, isn't reacting in a vacuum. It's reacting inside a body whose oxidative and microbial conditions shape how loud the alarm gets — which is the opening a molecule like hydrogen would have to exploit if it does anything here at all.

Hydrogen's proposed role traces back to a single, unusual property that researchers first characterized in 2007 and have documented across many organ systems since. Molecular hydrogen appears to neutralize the most cytotoxic reactive oxygen species — the hydroxyl radical and peroxynitrite — while leaving alone the milder reactive oxygen species that cells rely on for normal signaling. That selectivity is the whole reason hydrogen is interesting here. A blunt antioxidant that mops up every free radical can switch off useful immune messaging along with the harmful oxidation. A selective one, at least in theory, can lower the damaging oxidative load without silencing the signals a working immune system depends on.

Beyond direct scavenging, reviews of the field describe a second, indirect mechanism: hydrogen appears to nudge the Nrf2 pathway, the regulatory switch that turns on a cell's own antioxidant and detoxification genes. Nrf2 keeps surfacing in allergic-inflammation research because the same oxidative stress that damages tissue also amplifies the Th2 response — so a molecule that steadies Nrf2 has a plausible route into calming allergic inflammation rather than only cleaning up after it. The distinction between direct scavenging and Nrf2 signaling matters, because the second mechanism means hydrogen could keep influencing a cell long after the gas itself has diffused away.

Underneath both the fast and slow arms of allergy sits IgE, the antibody class that defines allergic sensitization. Once a person's immune system has been primed to treat a harmless protein as a threat, it produces IgE tuned to that specific allergen, and those antibodies arm the mast cells and eosinophils for the next encounter. Serum IgE is why allergy researchers keep measuring the same marker across otherwise unrelated studies — a drop in IgE is a signal that the sensitized state itself, not just a single flare, may be easing. Several of the hydrogen studies below report exactly that: lower IgE alongside lower symptom scores, in both animal models and human nasal trials.

Some of the most specific mechanistic evidence comes from the lower airway. In a laboratory model of asthma, Zhang et al. (2021), publishing in Inflammation Research, reported that hydrogen inhibited the IL-33/ILC2 axis — an upstream alarm signal that recruits and activates group 2 innate lymphoid cells, which are among the key drivers of allergic-type lung inflammation — in mice sensitized to ovalbumin. It's a mouse model, not a person. But it points at a specific, testable target rather than a vague antioxidant hand-wave, and it sets up a pattern the rest of the research keeps repeating: hydrogen acting on the machinery of the allergic response, not just its aftermath.

Mast Cells, Histamine, and the IgE Trigger

The Th2 cascade explains the slow, smoldering side of allergy. The fast side — the sneeze within seconds of exposure, the sudden welt, the immediate itch — runs through a different cell entirely: the mast cell. Mast cells sit in the tissues that meet the outside world (the nose, the airway, the gut lining, the skin), studded with a receptor called FcεRI that grabs onto IgE antibodies. When an allergen cross-links those IgE molecules, the mast cell degranulates, spilling histamine and a cascade of other mediators in a fraction of a second. That release is what a person feels as an allergic reaction.

This is where one of the earliest pieces of hydrogen-and-allergy research comes in. Itoh et al. (2009), publishing in Biochemical and Biophysical Research Communications, reported that oral intake of hydrogen-rich water blunted an immediate-type allergic reaction in mice. Working with cultured mast cells, the researchers traced the effect to a specific step: hydrogen attenuated the phosphorylation of Lyn, an enzyme just downstream of the FcεRI receptor, which in turn dampened the signal telling the cell to degranulate. They also described a feed-forward loop — the receptor signaling drives reactive oxygen production, and that reactive oxygen amplifies the signaling right back — that hydrogen appeared to interrupt at the oxidative step. It's a tidy piece of mechanism: a physical gas acting on a molecular switch that sits at the very start of the allergic reaction.

That mechanism matters because it reaches conditions the nasal trials don't directly test. Chronic urticaria — recurring hives — is fundamentally a mast-cell disorder, driven by the same histamine release, and it surfaces repeatedly in discussions of where hydrogen research might eventually look. Honesty requires stating the obvious limit here. No published trial has tested hydrogen water or hydrogen inhalation against chronic urticaria in people. The connection is mechanistic, not clinical. What the Itoh work establishes is a plausible biological route — hydrogen touching the mast-cell trigger itself — that would need its own dedicated human study before anyone could responsibly say more.

The histamine angle also reframes what "anti-allergic properties" would even mean for a molecule like hydrogen. It isn't an antihistamine. It doesn't block the histamine receptor the way a standard allergy pill does. The research instead points to hydrogen acting further upstream, on the oxidative conditions that make mast cells and Th2 cells quicker to fire — a different lever, pulled in a different place, with a much thinner evidence base behind it so far. For anyone weighing what the science does and doesn't support, that upstream-versus-receptor distinction is one of the most useful things to hold onto.

The mast-cell finding also helps explain why the same molecule keeps showing up in studies of such different-looking conditions. Rhinitis, asthma, atopic dermatitis, and hives don't obviously belong together — one is a runny nose, one is a tight chest, two are skin complaints. What unites them at the cellular level is heavy reliance on IgE, mast cells, and Th2 signaling, the exact machinery the hydrogen research keeps touching. A treatment aimed at a single symptom would have no reason to generalize across all four. A mechanism aimed at the shared upstream biology would — which is the logic, still largely unproven in humans, behind studying hydrogen across the whole allergic spectrum at once.

Eosinophils and the Alarm Signals of Allergic Inflammation

If mast cells fire the opening shot, eosinophils are the reinforcements that keep allergic inflammation going. These cells accumulate in allergic tissue and release proteins — eosinophil cationic protein, or ECP, chief among them — that damage the surrounding lining and sustain the inflammatory state. Eosinophil count and ECP level are two of the numbers allergy researchers reach for most often, because they track the intensity of the response rather than just its presence.

A cluster of controlled animal studies has looked specifically at what hydrogen does to those numbers. Yu et al. (2017), in the Journal of Inflammation, worked with a guinea pig model of allergic rhinitis and reported that hydrogen-rich saline lowered reactive oxygen species and malondialdehyde (a marker of oxidative damage), raised superoxide dismutase (a natural antioxidant enzyme), and — alongside those chemistry shifts — reduced the frequency of sneezing and scratching. The eosinophil story was the striking part. Blood eosinophil counts fell, serum ECP dropped, and the expression of eotaxin, the chemical signal that summons eosinophils into tissue, declined in the nasal lining. The researchers framed the effect as protective and rooted it in hydrogen's antioxidation, not in any direct anti-eosinophil drug action.

Guinea pigs turn up often in this corner of the literature for a specific reason: their nasal and airway responses to allergen sensitization resemble the human allergic reaction more closely than a mouse's do, which makes them a common stand-in for early allergic-rhinitis work. That doesn't erase the translational gap — a sensitized guinea pig is still not a person with hay fever — but it does mean the eosinophil and ECP readouts these studies moved are the same markers clinicians watch in human allergic disease. When the guinea-pig work and the human nasal trials point at the same numbers falling, the two bodies of evidence reinforce each other rather than talking past one another.

Two companion studies from overlapping research groups filled in the cytokine and regulatory picture. Zhao et al. (2017), in Allergologia et Immunopathologia, reported that hydrogen-rich saline lowered serum IgE along with the Th2 cytokines interleukin-4 and interleukin-13 in the same guinea pig allergic-rhinitis model, and reduced their expression in the nasal mucosa. Xu et al. (2018), in Inflammation, came at it from the regulatory side: they reported that hydrogen-rich saline increased the number and activity of CD4+CD25+Foxp3+ regulatory T cells — the immune system's own brakes — and raised the anti-inflammatory signals interleukin-10 and transforming growth factor-β, nudging the Th1/Th2 balance back toward center. Between them, the two papers describe hydrogen affecting both the accelerator and the brake of the allergic response in AR patients' animal counterparts.

Read together, these studies sketch a consistent mechanistic arc across the immune system: fewer eosinophils, lower IgE, quieter Th2 cytokines, more regulatory T-cell activity. Every one of them is an animal model, and every one uses hydrogen-rich saline delivered by injection rather than a glass of water — a distinction that matters, and one the authors themselves are careful about. What they collectively offer isn't proof of a human benefit. It's a coherent biological hypothesis, tested repeatedly in the same direction, that the human nasal trials were built to probe. The gap between "consistent in guinea pigs" and "demonstrated in people" is precisely the gap the clinical studies below try to narrow.

Why Oxidative Stress and Allergic Inflammation Travel Together

A reasonable question runs underneath all of this: why would an antioxidant have anything to do with allergies at all? Allergy sounds like an immune problem, not an oxidation problem. The research answer is that in allergic disease the two are hard to pull apart.

Allergic inflammation generates reactive oxygen species as a byproduct of immune cells doing their work, and that oxidative load then feeds back to intensify the inflammation — the same feed-forward pattern seen at the level of a single mast cell, scaled up to a whole inflamed tissue. Reviews of the respiratory-hydrogen literature describe this loop in detail: eosinophils and neutrophils arriving at an allergic site release oxidants, the oxidants damage the epithelial barrier and switch on inflammatory signaling, and the damaged, activated tissue recruits still more inflammatory cells. Oxidative stress isn't only a side effect of allergic inflammation. It's one of the engines that keeps it running.

That framing is what makes a selective antioxidant a plausible allergy intervention rather than a category error. There is also a metabolic dimension that a 2020 study brought into focus. Niu et al. (2020), publishing in Scientific Reports, reported that allergic airway inflammation in mice is accompanied by an energy metabolic pathway switch — immune cells shifting from mitochondrial oxidative phosphorylation toward aerobic glycolysis, the same kind of metabolic reprogramming seen in other inflammatory states. Treating the animals with hydrogen reversed that switch, turning glycolytic enzyme activity back down and mitochondrial activity back up, and reduced airway inflammation along the way.

None of this makes hydrogen unique in touching oxidative stress — plenty of antioxidants do — but the selectivity is the part that keeps drawing researchers back. A conventional antioxidant taken at high enough doses can interfere with the redox signaling immune cells rely on to function normally, which is one theory for why some antioxidant supplements have underwhelmed in inflammatory conditions. A molecule that preferentially quenches the hydroxyl radical and peroxynitrite, while leaving ordinary signaling oxidants largely alone, would sidestep that problem in principle. Whether it does so meaningfully in a living allergic patient is the question the human trials are only beginning to answer.

The energy-metabolism finding is worth holding loosely — it's one mouse study, and the mechanisms it describes are still being mapped. But it fits the larger pattern. Across scavenging of the hydroxyl radical, the Nrf2 pathway, mast-cell signaling, eosinophil recruitment, and now cellular energy metabolism, the research keeps describing hydrogen as acting on the abundance of oxidative and inflammatory signals rather than on any single allergy target. That breadth is either the most notable thing about it or the most frustrating, depending on how much a reader wants a clean, one-mechanism story. Either way, it explains why the same molecule keeps appearing in studies of the nose, the airway, and the skin at once.

The Nasal Flora Study That Reframed the Conversation

The most direct human data on hydrogen and allergy comes from Wang et al. (2024), a trial registered with the China Clinical Trial Registry (ChiCTR2200062253) and published in the World Allergy Organization Journal. Instead of testing hydrogen against a single symptom, the research team asked something more specific: does hydrogen inhalation change the bacterial ecosystem living inside an allergic nose — and does that change track with symptom improvement?

What the Researchers Measured

Patients diagnosed with allergic rhinitis inhaled hydrogen gas, and researchers tracked eosinophil count, IgE concentration, a visual analog symptom scale, the total nasal symptom score, and a validated rhinoconjunctivitis quality-of-life questionnaire, comparing results before and after. They also ran 16S rRNA gene sequencing on nasal flora samples, comparing allergic patients against healthy controls both before and after hydrogen inhalation.

What They Found

There were no adverse reactions during or after hydrogen inhalation, and the researchers reported significant improvements across the visual analog scale, total nasal symptom score, eosinophil count, and IgE (P < 0.05). The flora data added something genuinely new: allergic patients showed a higher abundance of two bacterial groups — Ruminococcus and Erysipelotrichaceae — than healthy controls, and hydrogen inhalation down-regulated both. A third species, Blautia faecis, increased after hydrogen inhalation and correlated negatively with symptom severity. The authors stayed careful about their own conclusion: hydrogen "may improve symptoms in AR patients by modulating the distribution of nasal flora," and they explicitly called for larger trials to test the hypothesis further. That's a researcher describing a real, measured signal — not overselling it.

The design choice is what makes this study worth dwelling on. Most allergy research measures the response — the eosinophils, the IgE, the symptom scores — and stops there. By adding 16S rRNA sequencing of the nasal microbiome, the team was reaching for a possible upstream cause, asking whether hydrogen's symptom effect might run partly through the bacterial ecosystem rather than through the immune cascade alone. That doesn't prove the flora shift caused the symptom improvement; correlation across a small sample can't carry that weight, and the authors don't claim it does. What it does is generate a specific, falsifiable hypothesis for the next study to test, which is how a young research area is supposed to move. The measured restraint in the conclusion — "may improve," "modulating the distribution," a call for more data — is the tell that this is careful science rather than a marketing claim dressed up in a journal.

The Randomized Trial Behind Hydrogen-Rich Saline

Two years before the nasal-flora study, a different research group had already run a larger, more traditional randomized controlled trial on a related question: does irrigating the nasal cavity with hydrogen-rich saline, rather than plain saline, actually change chronic rhinitis symptoms?

A 120-Patient Double-Blind Design

Jin et al. (2022), publishing in the Journal of Inflammation Research, randomized 120 patients with chronic rhinitis into two groups — one irrigating with hydrogen-rich saline, the other with ordinary normal saline — in a double-blind design. Researchers tracked the total nasal symptom score as the primary outcome, alongside eosinophilic protein in nasal secretions, nasal nitric oxide, and regulatory T-cell and B-cell populations: a genuinely thorough immunological workup for a nasal-irrigation study.

Results Across Chronic and Allergic Rhinitis

Compared with plain saline, hydrogen-rich saline irrigation improved chronic rhinitis symptoms, and the improvement was most pronounced specifically in the subgroup of patients with allergic rhinitis. The same research team, writing a dedicated 2023 review of the hydrogen-and-nasal-inflammation literature in the same journal, was candid about where the field actually stands: both the basic research and the clinical studies remain at what they called an observational level, with small sample sizes and short study duration. Fair. That's exactly why a 120-patient randomized trial is worth taking seriously — it's larger than most of what's been published in this specific niche.

The immunological workup is the part that separates this trial from a simple symptom survey. Alongside the total nasal symptom score, the researchers tracked eosinophilic protein in nasal secretions, nasal nitric oxide, and regulatory T-cell and B-cell populations — the cellular machinery underneath the sneezing and congestion, not just the sneezing and congestion themselves. That the strongest effect landed in the allergic-rhinitis subgroup fits the mechanism cleanly: if hydrogen works by calming a Th2-driven, oxidatively amplified response, the patients whose rhinitis is most clearly allergic would be expected to show the largest effect. A subgroup finding in a single trial isn't a guarantee it will replicate. But a subgroup finding that lines up with the proposed biology is more persuasive than one that appears out of nowhere.

A Post-Surgical Nasal Irrigation Trial

A follow-up randomized, double-blind trial from an overlapping author group pushed the same intervention into a different setting: recovery after chronic rhinosinusitis surgery. Sixty-one post-surgical patients rinsed their nasal cavity with either hydrogen-rich saline or normal saline, followed weekly for twelve weeks using a visual analog score, the 22-item Sinonasal Outcomes Test, and endoscopy scoring. Researchers reported that epithelialization — the nasal lining actually healing over — took 6.61 weeks on average in the hydrogen-rich saline group, versus 9.97 weeks with plain saline, and that short-term complete control was reported in 20 of 31 hydrogen-saline patients versus 11 of 30 in the saline-only group. That is a shorter average epithelialization time in one randomized, controlled, post-surgical population, not a subjective symptom score alone.

Epithelialization time is a useful outcome precisely because it's hard to fake with expectation. A patient can talk themselves into feeling less congested; a nasal lining either heals over on endoscopy or it doesn't, and the person scoring that endoscopy in a double-blind trial doesn't know which rinse each patient received. Reading roughly three weeks off an average healing timeline — 6.61 weeks versus 9.97 — in that kind of controlled, objectively scored setting is among the more concrete results in the whole allergy-adjacent hydrogen literature. It's still one trial in one surgical population, and it earns the same "needs replication" caveat as everything else here. The difference is that the outcome it moved is a physical one.

What About Skin Allergies? The Atopic Dermatitis Pilot

Allergic disease doesn't stop at the nose. Atopic dermatitis — the chronic, itchy skin condition closely tied to the same Th2-driven allergic pathway — has its own small hydrogen study, and it's worth reporting honestly: this one is a pilot, not a definitive trial.

Hu et al. (2024), publishing in Advances in Integrative Medicine, had six patients with atopic dermatitis bathe in hydrogen-rich water daily for eight weeks. Researchers reported that rash severity and itching both improved over the study period, particularly on the trunk and limbs — the areas that could actually be fully immersed in the bathwater. Six patients is a small number, and the researchers frame this explicitly as a pilot meant to justify a larger trial, not a conclusion in its own right. That's the right way to read it: a genuinely interesting early signal in a delivery method — bathing, rather than drinking or inhaling — that most hydrogen research doesn't touch at all.

A second, older study looked at hydrogen delivered the way most people would actually use it — by drinking it. Ignacio et al. (2013), publishing in Evidence-Based Complementary and Alternative Medicine, gave NC/Nga mice with dust-mite-induced atopic dermatitis either hydrogen water or purified water for twenty-five days. The researchers reported that the hydrogen-water group had significantly lower serum levels of several immune signals tied to the allergic response — including interleukin-10, tumor necrosis factor-α, interleukin-12p70, and GM-CSF — and interpreted the results as hydrogen water modulating both the Th1 and Th2 arms of the response. Their framing was cautious and forward-looking: a first note on the drinking effect of hydrogen water on atopic dermatitis, offered as a reason to investigate further rather than a finished answer.

Atopic dermatitis, eczema, and allergic contact dermatitis all share a common thread with the nasal and airway research — oxidative stress woven through the inflammation. In allergic contact dermatitis specifically, the rash a person develops in response to nickel, a fragrance, or a preservative, the chemical triggers provoke reactive oxygen production in the skin, and the Nrf2 antioxidant pathway is one of the main systems the skin uses to keep that reaction in check. That's the same Nrf2 pathway hydrogen appears to influence elsewhere, which is why researchers reviewing the skin literature keep flagging molecular hydrogen as a candidate worth testing. The honest status is that the human skin data stays thin: one small bathing pilot, one older drinking study in mice, and a mechanistic rationale that hasn't yet been put through a large controlled trial in eczema or contact dermatitis. Preliminary, unfinished, and clearly labeled as both.

The Asthma Question: What the Research Suggests

Asthma is the allergic condition with the deepest hydrogen literature, and also the one where human data lags furthest behind the mechanism. Most of what's published so far is preclinical — done in mice, not people.

Two independent research groups working four years apart arrived at overlapping conclusions through different experimental setups. One, in 2021, found that hydrogen blocked the IL-33/ILC2 alarm pathway in ovalbumin-sensitized asthmatic mice. Another, in 2025, found that hydrogen inhalation reduced airway hyperreactivity, lowered the Th2 cytokines interleukin-4, interleukin-5, and interleukin-13, and raised the regulatory cytokines interleukin-10 and TGF-β1 associated with dialing an immune response back down. Li et al. (2025), the more recent of the two, published their work in the European Journal of Medical Research. When two teams using different models and different readouts land on the same picture, that convergence is a meaningfully different kind of evidence than either study would represent standing alone — though it remains, in both cases, evidence from animals.

The human evidence is thinner, but it exists. Wang et al. (2020), publishing in QJM, had 20 patients — 10 with asthma, 10 with COPD — inhale a hydrogen-containing steam mixture for 45 minutes in a single session, then measured inflammatory cytokines in peripheral blood. It's a small, acute, single-session study, not a multi-week trial, and not blinded the way the nasal studies above were. Researchers reported measurable changes in airway inflammatory markers after that one session. Nobody should read a single 45-minute inhalation as equivalent to the weeks-long protocols used in the nasal-rhinitis trials. It's an early data point in a specific patient population, and it's labeled that way here on purpose.

What the asthma work adds to the broader picture is a lower-airway version of the same story the nose and skin research tell. The Th2 cytokines fall, the regulatory signals rise, the oxidative markers ease, and the airway inflammation quiets — across multiple independent models. The distance between that consistent animal signal and the near-absence of controlled human asthma trials is exactly the distance the field openly acknowledges it still has to cover. It's an early thread, not a finished one.

Putting It in Context: A Fast-Growing Body of Research

None of the studies above exist in isolation. Johnsen et al. (2023), reviewing the clinical hydrogen literature in Molecules, catalogued 81 identified clinical trials and 64 human publications spanning cardiovascular disease, metabolic conditions, cancer support, and respiratory illness. A newer 2025 review, Zajac et al., writing in the International Journal of Molecular Sciences, took a narrower angle specifically on respiratory disease, summarizing twenty years of hydrogen research across allergies, asthma, COPD, pulmonary fibrosis, and lung injury.

More than 2,000 published studies and over 80 human clinical trials now exist across the broader molecular hydrogen research base, and while allergic disease specifically is one of the newer corners of that literature — smaller trials, shorter follow-up periods, more preclinical work relative to human data than in some other areas — the trajectory across nasal inflammation, skin, and airway research all points in the same direction this series keeps finding elsewhere: early signals from small studies, not a settled case.

Within that larger body of work, the allergy-specific slice is small but internally consistent. Human nasal trials, controlled animal models of rhinitis, a skin pilot, mouse asthma studies, and mechanistic work on mast cells and eosinophils all point the same way, even as every individual study carries the usual early-stage caveats: modest sample sizes, short follow-up windows, and a heavy reliance on animal models for the deepest mechanisms. The value of a review like Zajac et al. (2025) is that it lets a reader see the whole shape at once rather than one study at a time. And the shape, for allergic and respiratory disease, is an active, still-maturing field rather than a closed question — which is exactly why the researchers doing the work keep pairing every positive result with a call for larger trials.

Frequently Asked Questions

What have the human studies on hydrogen and allergic rhinitis reported?

Researchers have reported changes in nasal symptom scores, eosinophil counts, and IgE levels after hydrogen inhalation or hydrogen-rich saline irrigation in allergic rhinitis patients, and a six-person pilot reported changes in atopic dermatitis symptom scores after hydrogen-water bathing. These are small, early studies; none establishes that hydrogen treats or cures allergic disease, and the researchers themselves are calling for larger trials.

Is this research about drinking hydrogen water, or something else?

Both, depending on the study. The nasal trials used hydrogen inhalation or hydrogen-rich saline irrigation, the atopic dermatitis pilot used hydrogen-water bathing, and the asthma research spans both inhalation and mouse-model work. No study in this specific research area has directly tested drinking hydrogen-rich water for allergy symptoms specifically, which is worth saying plainly rather than blurring the delivery methods together.

Did any study look at seasonal allergies specifically?

No. The largest randomized trial, Jin et al. (2022), enrolled patients with chronic rhinitis broadly and reported the largest difference within the allergic-rhinitis subgroup. No study has isolated seasonal, pollen-triggered allergies as their own category.

Is there any research specifically on hydrogen and hives or chronic urticaria?

Not directly. No published clinical trial has tested hydrogen water or hydrogen inhalation against chronic urticaria in people. The reason it comes up at all is mechanistic: hives are driven by mast-cell degranulation and histamine release, and a 2009 laboratory study found that hydrogen could dampen the mast-cell signaling that triggers that release in cells and in mice. That's a plausible biological rationale, not clinical evidence — a distinction worth keeping firmly in mind before drawing any conclusion about hydrogen and urticaria.

How long did people in these studies use hydrogen before researchers measured changes?

It varied by study. The nasal-irrigation trials ran their protocols over weeks. The atopic dermatitis bathing pilot used eight weeks of daily immersion. The single human asthma-and-COPD data point came from one 45-minute session, which is why it should be read as preliminary rather than conclusive.

What mechanisms do the studies describe?

Rather than blocking a histamine receptor the way an antihistamine does, the studies describe hydrogen acting on upstream conditions — oxidative stress, mast-cell and eosinophil signaling, the Th1/Th2 balance, regulatory T-cell activity. Most of that mechanistic work is in animal models. Whether it translates into a difference in people is the open question the existing trials are too small and too short to answer.

What do the studies report about safety?

The human trials summarized above reported no adverse reactions. No published research has examined interactions between molecular hydrogen and antihistamines, nasal steroids, or other allergy medications, so that question is unstudied rather than answered. Anyone managing a diagnosed condition or taking prescription medication should talk to their healthcare provider before changing anything, per the disclaimer below.

References

Wang N, Ma Q, Zhai J, Che Y, Liu J, Tang T, Sun Y, Wang J, Yang W. Hydrogen inhalation: A novel approach to alleviating allergic rhinitis symptoms by modulating nasal flora. World Allergy Organization Journal. 2024;17(10):100970. PMID: 39308790. PMC: PMC11415863. DOI: 10.1016/j.waojou.2024.100970.
Jin L, Fan K, Tan S, Liu S, Ge Q, Wang Y, Ai Z, Yu S. The Beneficial Effects of Hydrogen-Rich Saline Irrigation on Chronic Rhinitis: A Randomized, Double-Blind Clinical Trial. Journal of Inflammation Research. 2022;15:3983-3995. PMID: 35873384. DOI: 10.2147/JIR.S365611.
Jin L, Fan K, Yao C, Chang Y, Wang Y, Lu J, Yu S. Clinical Observation of Hydrogen-Rich Saline for Nasal Irrigation After Surgery for Chronic Sinusitis: A Randomized, Double-Blind, Controlled Trial. Journal of Inflammation Research. 2024;17:7361-7372. PMID: 39429848. PMC: PMC11490253. DOI: 10.2147/JIR.S476646.
Jin L, Tan S, Fan K, Wang Y, Yu S. Research Progress of Hydrogen on Chronic Nasal Inflammation. Journal of Inflammation Research. 2023;16:2149-2157. PMID: 37220503. DOI: 10.2147/JIR.S413179.
Hu A, Yamaguchi T, Tabuchi M, et al. A pilot study to evaluate the potential therapeutic effect of hydrogen-water bathing on atopic dermatitis in humans. Advances in Integrative Medicine. 2024;11(1):2-9. DOI: 10.1016/j.aimed.2023.10.003.
Zhang J, Feng X, Fan Y, Zhu G, Bai C. Molecular hydrogen alleviates asthma through inhibiting IL-33/ILC2 axis. Inflammation Research. 2021;70:569-579. PMID: 33852061. DOI: 10.1007/s00011-021-01459-w.
Li H, Qi X, Xu H, Zhou R, Liu X, Li L, Hu C, Dai C. Hydrogen inhalation ameliorates lung inflammation in mice with asthma. European Journal of Medical Research. 2025;30:1024. PMID: 41146240. PMC: PMC12560338. DOI: 10.1186/s40001-025-03296-7.
Wang ST, Bao C, He Y, et al. Hydrogen gas (XEN) inhalation ameliorates airway inflammation in asthma and COPD patients. QJM: An International Journal of Medicine. 2020;113(12):870-875. PMID: 32407476.
Johnsen HM, Hiorth M, Klaveness J. Molecular Hydrogen Therapy-A Review on Clinical Studies and Outcomes. Molecules. 2023;28(23):7785. PMID: 38067515. PMC: PMC10707987. DOI: 10.3390/molecules28237785.
Zajac D, Jampolska M, Wojciechowski P. Molecular Hydrogen in the Treatment of Respiratory Diseases. International Journal of Molecular Sciences. 2025;26(9):4116. PMID: 40362357. DOI: 10.3390/ijms26094116.
Itoh T, Fujita Y, Ito M, Masuda A, Ohno K, Ichihara M, Kojima T, Nozawa Y, Ito M. Molecular hydrogen suppresses FcεRI-mediated signal transduction and prevents degranulation of mast cells. Biochemical and Biophysical Research Communications. 2009;389(4):651-656. PMID: 19766097. DOI: 10.1016/j.bbrc.2009.09.047.
Yu S, Zhao C, Che N, Jing L, Ge R. Hydrogen-rich saline attenuates eosinophil activation in a guinea pig model of allergic rhinitis via reducing oxidative stress. Journal of Inflammation. 2017;14:1. PMID: 28100959. PMC: PMC5237150. DOI: 10.1186/s12950-016-0148-x.
Zhao C, Yu S, Li J, Xu W, Ge R. Changes in IL-4 and IL-13 expression in allergic-rhinitis treated with hydrogen-rich saline in guinea-pig model. Allergologia et Immunopathologia. 2017;45(4):350-355. PMID: 28215576. DOI: 10.1016/j.aller.2016.10.007.
Xu F, Yu S, Qin M, Mao Y, Jin L, Che N, Liu S, Ge R. Hydrogen-Rich Saline Ameliorates Allergic Rhinitis by Reversing the Imbalance of Th1/Th2 and Up-Regulation of CD4+CD25+Foxp3+ Regulatory T Cells, Interleukin-10, and Membrane-Bound Transforming Growth Factor-β in Guinea Pigs. Inflammation. 2018;41(1):81-92. PMID: 28894978. DOI: 10.1007/s10753-017-0666-6.
Niu Y, Nie Q, Dong L, Zhang J, Liu SF, Song W, Wang X, Wu G, Song D. Hydrogen Attenuates Allergic Inflammation by Reversing Energy Metabolic Pathway Switch. Scientific Reports. 2020;10:1962. PMID: 32029879. PMC: PMC7005324. DOI: 10.1038/s41598-020-58999-0.
Ignacio RMC, Kwak HS, Yun YU, Sajo MEJV, Yoon YS, Kim CS, Kim SK, Lee KJ. The Drinking Effect of Hydrogen Water on Atopic Dermatitis Induced by Dermatophagoides farinae Allergen in NC/Nga Mice. Evidence-Based Complementary and Alternative Medicine. 2013;2013:538673. PMID: 24348704. PMC: PMC3852999. DOI: 10.1155/2013/538673.